Beta-ketoacyl-ACP reductase
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
== Function == | == Function == | ||
| - | '''Beta-ketoacyl carrier protein reductase''' (BKACPR) catalyzes the reaction of conversion of 3-hydroxyacyl-[acyl-carrier-protein] to 3-oxoacyl-[acyl-carrier-protein] while using NADPH as a reducing agent. BKACPR is part of the fatty acid biosynthesis pathway. | + | '''Beta-ketoacyl carrier protein reductase''' (BKACPR) catalyzes the reaction of conversion of 3-hydroxyacyl-[acyl-carrier-protein] to 3-oxoacyl-[acyl-carrier-protein] while using NADPH as a reducing agent. BKACPR is part of the type II fatty acid biosynthesis pathway. |
== Disease == | == Disease == | ||
== Relevance == | == Relevance == | ||
| + | |||
| + | BKACPR from ''Plasmodium falciparium'' inhibitors are tested as antimalarial drugs. Other BKACPR inhibitors are tested for combating toxoplasmosis and sleeping sickness. | ||
== Structural highlights == | == Structural highlights == | ||
| + | |||
| + | The active site interacting with co-factor NADPH contains the active site triad Ser, Tyr, Arg. | ||
</StructureSection> | </StructureSection> | ||
Revision as of 10:07, 10 November 2015
| |||||||||||
3D structures of beta-ketoacyl carrier protein reductase
Updated on 10-November-2015
